NCT04207463 - A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

June 3, 2020

Primary Completion Date

December 31, 2020

Study Completion Date

May 30, 2021

Conditions

Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Interventions

DRUG

AK105

AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.

DRUG

Anlotinib

a multi-target receptor tyrosine kinase inhibitor

Trial Locations (7)

100021

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

100730

NOT_YET_RECRUITING

Beijing Hospital, Beijing

NOT_YET_RECRUITING

Peking Union Medical College Hospital, Beijing

150081

NOT_YET_RECRUITING

Harbin Medical University Cancer Hospital, Harbin

210009

RECRUITING

Jiangsu Cancer Hospital, Nanjing

250013

RECRUITING

Jinan Central Hospital, Jinan

710061

NOT_YET_RECRUITING

Shanxi Provincial Cancer Hospital, Xi’an